Table of Content

1. EXECUTIVE SUMMARY

2. INTRODUCTION
2.1. Overview of SARM1
2.2. Role of SARM1 in Neurodegenerative Disorders
2.2.1. Mechanism of Action of SARM1
2.3. Mechanism of SARM1 Pathway Inhibition
2.4. Future Perspectives of SARM1 inhibitors Therapeutics

3. MARKET LANDSCAPE
3.1. SARM1 Inhibitors: Pipeline Review
3.1.1 Analysis by Phase of Development
3.1.2. Analysis by Type of Molecule
3.1.3. Analysis by Phase of Development and Type of Molecule
3.1.4. Analysis by Target Indication
3.1.5. Analysis by Type of Developers
3.1.6. Analysis by Phase of Development and Target Indication
3.2. SARM1 Inhibitors: Developer Landscape
3.2.1. Analysis by Year of Establishment
3.2.2. Analysis by Company Size
3.2.3. Leading Developers: Analysis by Number of Candidates
3.2.4. Regional Landscape by Type of Player

4. COMPANY COMPETITIVENESS ANALYSIS
4.1. Assumptions and Key Parameters
4.2. Methodology
4.3. Company Competitive Analysis: Industry Players
4.4. Company Competitive Analysis: Non-Industry Players

5. COMPANY PROFILES
5.1. Disarm Therapeutics
5.1.1. Company Overview
5.1.2. Product Portfolio
5.1.3. Recent Patent Portfolio
5.1.4. Recent Developments and Future Outlook
5.2. Nura Bio
5.2.1. Company Overview
5.2.2. Product Portfolio
5.2.3. Recent Patent Portfolio
5.2.4. Recent Developments and Future Outlook
5.3. Washington University
5.3.1. Company Overview
5.3.2. Product Portfolio
5.3.3. Recent Patent Portfolio
5.3.4. Recent Developments and Future Outlook

6. PUBLICATION ANALYSIS
6.1. Methodology and Parameters
6.2. SARM1 inhibitors Therapeutics: Publication Analysis
6.2.1. Analysis by Year of Publication
6.2.2. Analysis by Type of Publication
6.2.3. Most Popular Journals: Analysis by Number of Publications
6.2.4. Most Popular Journals: Analysis by Journal Impact Factor
6.2.5. Popular Keywords: Analysis by Key Focus Areas
6.2.6. Most Active Publishers: Analysis by Number of Publications
6.2.7. Most Popular Affiliations: Analysis by Number of Publications
6.2.8. Analysis by Geography

7. GRANT ANALYSIS
7.1. Scope and Methodology
7.2. Key Parameters
7.3. SARM1 inhibitors Therapeutics: Grant Analysis
7.3.1. Analysis by Year of Grant Awarded
7.3.2. Analysis by Support Period
7.3.3. Analysis by Amount Awarded
7.3.4. Analysis by Leading Funding Institute Centre
7.3.5. Analysis by Type of Grant
7.3.6. Analysis by Activity Code
7.3.7. Analysis by Study Section Involved
7.3.8. Analysis by Purpose of Grant
7.3.9. Prominent Program Officers: Analysis by Number of Grants
7.3.10. Popular Recipient Organizations: Analysis by Number of Grants and Amount Awarded
7.3.11. Most Popular Departments: Analysis by Number of Grants
7.3.12. Analysis by Location of Recipient

8. PATENT ANALYSIS
8.1. Scope and Methodology
8.2. Key Parameters
8.3. SARM1 inhibitors Therapeutics: Patent Analysis
8.3.1. Analysis by Type of Patent
8.3.2. Analysis by Publication Year
8.3.3. Analysis by Application Year
8.3.4. Analysis by Geography
8.3.5. Analysis by CPC Symbols
8.3.6. Analysis by Type of Applicant
8.3.7. Analysis by Focus Area
8.3.8. Analysis by Patent Age
8.3.9. Leading Industry Players: Analysis by Number of Patents
8.3.10. Leading Non-Industry Players: Analysis by Number of Patents
8.3.11. Leading Individual Assignees: Analysis by Number of Patents
8.4. SARM1 inhibitors Therapeutics: Patent Benchmarking Analysis
8.4.1. Analysis by Patent Characteristics
8.5. SARM1 inhibitors Therapeutics: Patent Valuation

9. RECENT DEVELOPMENTS
9.1. List of Recent Developments

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Key Parameters and Assumptions
10.2. Methodology
10.3. SARM1 inhibitors Therapeutics: List of Forecasted Drugs
10.4 Global SARM1 inhibitors Therapeutics Market, 2033, 2037 and 2040
10.4.1. SARM1 inhibitors Therapeutics Market: Distribution by Target Indication, 2037 and 2040
10.4.2. SARM1 inhibitors Therapeutics Market: Distribution by Type of Molecule, 2033, 2037 and 2040
10.4.3. SARM1 inhibitors Therapeutics Market: Distribution by Drug Developer, 2037 and 2040
10.4.4. SARM1 inhibitors Therapeutics Market: Distribution by Drug Candidate, 2037 and 2040
10.4.5. SARM1 inhibitors Therapeutics Market: Distribution by Geography, 2037 and 2040
10.5. SARM1 inhibitors Therapeutics Market: Forecast of Individual Product Sales
10.5.1 DSRM-3716 (Disarm Therapeutics): Sales Forecast
10.5.2 Unnamed Molecule 1 (Disarm Therapeutics): Sales Forecast
10.5.3 Unnamed Molecule 2 (Disarm Therapeutics): Sales Forecast
10.5.4 Unnamed Molecule 3 (Disarm Therapeutics): Sales Forecast
10.5.5 Unnamed Molecule (Nura Bio): Sales Forecast
10.5.6 Unnamed Molecule (King’s College London): Sales Forecast

11. APPENDIX 1: LIST OF FIGURES

12. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS